AHA PREVENT risk score progression

There is 1 paper on AHA PREVENT risk score progression in aging research: 1 trial in people.

Biomarker

1 paper studies it1 finding

1 new paper in 30 daysSee all 1 papers on AHA PREVENT risk score progression

  • Human trial1

Interventions

1

Finerenone

downin humans1

1 study
  1. Finerenone decreases AHA PREVENT risk score progression in humans (Base-model least squares mean difference −0.018 at Month 48; p<0.01; full-model reduction from Month 4, p<0.0001).

    “Finerenone significantly reduced the progression of PREVENTTM score relative to placebo at Month 48 using the base model”

    Human trialType 2 diabetes and chronic kidney disease without prior cardiovascular disease; base model versus placebo48 monthsn = 7,050

    Efficacy of Finerenone in Primary Cardiovascular Prevention: A Mechanistic Analysis Using the AHA PREVENT™ Risk Score

    AHA Scientific Sessions 2026 abstract

More on Finerenone

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 11 paper in 12 months